The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for ALTUVIIIO™ (Sanofi) to include the full results of the phase 3 XTEND-Kids clinical trial. ALTUVIIIO is a recombinant factor VIII…
Results of a new study published in the Journal of Blood Medicine (JBM), indicate that people with hemophilia A (HA) who have been on a prophylactic treatment regimen have a reduced risk for intracranial hemorrhage (ICH). Often…
For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Releases Statement on UK Infected Blood ScandalNBDF Stands…
#block-recentonlineeducation {
display:none;
}
Learn About Bispecific Antibody TherapyOne type of treatment option for hemophilia A is bispecific antibody therapy. In this 3D video we will show how this treatment works in the clotting cascade.…
Beth Whitehouse is the senior vice president of advancement for NBDF, responsible for creating, executing, and leading a comprehensive national development strategy and stakeholder relations program that enhances corporate and individual giving,…
NBDF's Wednesday Webinar SeriesJoin us for an enlightening webinar, "Breaking Barriers: Advancing Inclusivity in Inherited Bleeding Disorders," where we delve into the crucial topic of fostering inclusivity within the…